I have two main areas of research interests: the study of leishmaniasis and drug delivery.  My research on leishmaniasis has been involved in understanding the underlying immunological mechansims involved in the control of the disease, the mechananism responible for drug resistance, and development of novel vaccine fomulations to control the infection.  I work on L. donovani, L. major  and L. mexicana  and we have recently started using luciferase-expressing parasites to track the infection.   My drug delivery studies have focused on using non-ionic surfactant vesicles (NIV) to improve drug delivery by the intravenous or pulmonary routes. We are currently involved in commercialising NIV for the pulmonary delivery ('Inhalosomes') through the spin-out comany 'Inhalosome-C Ltd', which is involved in developing a cisplatin product for the treatment of lung cancer.

B10 Fo luc cells imaged using the IVIS® system

Cells were treated with an anticancer drug (columns 3-10) - with the highest concentration in colum 3 and the lowest in column 10.  Column 2 shows the results for the control cells and column 11 shows the results for the negative control. This type of assay is used for screening anticancer compounds.